ORPHA:881
Turner syndrome
Also known as: 45,X syndrome · 45,X/46,XX syndrome
Publications
25,843
97.5th percentile
Trials
47
Interventional, condition-specific
Researchers
1,165
Distinct authors in sample
Gene link
—
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare chromosomal anomaly syndrome characterized by complete or partial loss of an X chromosome in phenotypic females, clinically manifesting with short stature, primary ovarian insufficiency as well as cardiovascular, renal, liver, autoimmune diseases, hearing loss and neurocognitive abnormalities.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019499
- MeSH:D014424
- UMLS:C0041408
- NCIT:C26900
Additional Mondo synonyms (4)
45,X gonadal dysgenesis · 45,X0 syndrome · 45X syndrome · karyotype 45, X
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
25,843 matched papers (11,929 in last 10 years) Source
- Phenotype characterisedPresent
454 HPO annotations (e.g. Abnormal pinna morphology; Short toe; Celiac disease) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationPresent
2 FDA designations (1 FDA orphan-indication approval) — e.g. Oxandrolone Source
- Interventional trialPresent
47 matched on ClinicalTrials.gov (12 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
454
Associated phenotypes · MONDO:0019499
- Abnormal pinna morphology
- Short toe
- Celiac disease
- Cholestatic liver disease
- Scoliosis
Showing 5 of 454 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
2
Designations · 1 with FDA orphan-indication approval
- FDA OxandroloneShort stature Turner's Syndrome · 1990-07-05 · Not FDA Approved for Orphan Indication
- FDA Somatropin (Humatrope)Short stature Turner Syndrome · 1990-05-08
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
13
Drugs / clinical candidates · MONDO_0019499
- ESTRADIOL·phase 3
- ESTROGENS, CONJUGATED·phase 3
- ETHINYL ESTRADIOL·phase 3
- LONAPEGSOMATROPIN·phase 3
- MEDROXYPROGESTERONE ACETATE·phase 3
- OXANDROLONE·phase 3
- SOMAPACITAN·phase 3
- ESTRADIOL VALERATE·phase 2
- PROGESTERONE·phase 2
- TESTOSTERONE·phase 2
- ESTROGEN·unknown
- POLYETHYLENE GLYCOL·unknown
- SOMATROPIN·approval
CTD chemicals (MyDisease.info)
2 associated chemicals · 56 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Chromium · marker/mechanism
- Thiobarbituric Acid Reactive Substances · marker/mechanism
Pathways: Arginine biosynthesis; Arginine and proline metabolism; Tryptophan metabolism; Glyoxylate and dicarboxylate metabolism; Metabolic pathways; Carbon metabolism; Calcium signaling pathway; Cytokine-cytokine receptor interaction
Literature
Is anyone studying this?
25,843
25,843 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
25,843 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
11,929 in the last 10 years · medium confidence · 97.5th percentile (publications denominator)
Phrase hits: 25,843 · MeSH hits: 0
Who's working on it?
1,165
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li L4 papers · 2026
Yulin Women and Children Health Care Hospital, Yulin, Guangxi, China.
Papers in Europe PMC - 02Gutmark-Little I3 papers · 2026
Division of Pediatric Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Papers in Europe PMC - 03
- 04Jamalinia M3 papers · 2026
Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Papers in Europe PMC - 05Kim JH3 papers · 2026
Department of Pediatrics, Asan Medical Centre Children's Hospital, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address: pedkjh@amc.seoul.kr.
Papers in Europe PMC - 06Li Y3 papers · 2026
Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China.
Papers in Europe PMC - 07Liu X3 papers · 2026
Hunan Provincial Key Laboratory of Regional Hereditary Birth Defects Prevention and Control, Reproductive Medicine Center, Changsha Hospital for Maternal & Child Health Care, Hunan Normal University, 416 Chengnan Road, Yuhua District, Changsha, 410007, China.
Papers in Europe PMC - 08Lonardo A3 papers · 2026
Department of Internal Medicine, Azienda Ospedaliero-Universitaria Di Modena (-2023), Modena, Italy.
Papers in Europe PMC - 09Prakash SK3 papers · 2026
Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Papers in Europe PMC - 10Sowińska-Przepiera E3 papers · 2026
Pediatric, Adolescent Gynecology Clinic, Department of Gynecology, Endocrinology and Gynecological Oncology, Pomeranian Medical University in Szczecin, Unii Lubelskiej 1, 71-252 Szczecin, Poland.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
47
interventional trials for this specific condition
47 interventional trials matched this specific condition name; 12 currently recruiting in our sample.
Data as of 11 September 2026
47 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 97th percentile).
medium confidence · 97th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
47 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04252001·NOT YET RECRUITING·Growing up With the Young Endocrine Support System (YESS!)
Not reviewed·Conditions: Congenital Adrenal Hyperplasia · Hypogonadotropic Hypogonadism · Growth Hormone Deficiency · Combined Pituitary Hormone Deficiency·Matched via name phrase
- NCT06544473·RECRUITING·Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome
Not reviewed·Conditions: Turner Syndrome · Hypogonadism; Ovarian · Hormone Replacement Therapy · Estrogen Replacement Therapy·Matched via name phrase
- NCT06202846·RECRUITING·Identification of Y Chromosome From Free Circulating DNA in Patients With Turner Syndrome
Not reviewed·Conditions: Turner Syndrome·Matched via name phrase
- NCT07041814·NOT YET RECRUITING·A Study Comparing Different Treatment Approaches for the Initiation of Puberty in Girls With Turner Syndrome Using a TRIFECTA-DARED Approach for Rare Diseases
Not reviewed·Conditions: Turner Syndrome·Matched via name phrase
- NCT03836300·ENROLLING BY INVITATION·Parent and Infant Inter(X)Action Intervention (PIXI)
Not reviewed·Conditions: Fragile X Syndrome · Angelman Syndrome · Prader-Willi Syndrome · Dup15Q Syndrome·Matched via name phrase
- NCT07221851·RECRUITING·Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Not reviewed·Conditions: Turner Syndrome · Short Stature Homeobox Gene Mutation · Idiopathic Short Stature · Small for Gestational Age at Delivery·Matched via name phrase
- NCT06834594·RECRUITING·Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome
Not reviewed·Conditions: Turner Syndrome · Primary Ovarian Insufficiency (Poi)·Matched via name phrase
- NCT06780514·RECRUITING·Cardiopulmonary Exercise Testing in Girls (8-18y) with Turner Sydrome.
Not reviewed·Conditions: Turner Syndrome·Matched via name phrase
- NCT06570460·RECRUITING·Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome
Not reviewed·Conditions: Turner Syndrome · Hypogonadism; Ovarian · Hormone Replacement Therapy · Estrogen Replacement Therapy·Matched via name phrase
- NCT07614152·RECRUITING·The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
Not reviewed·Conditions: Turner Syndrome·Matched via name phrase
- NCT05849389·RECRUITING·Vosoritide for Short Stature in Turner Syndrome
Not reviewed·Conditions: Turner Syndrome · Short Stature·Matched via name phrase
- NCT05740579·RECRUITING·The Danish TURNER Cryopreservation Study
Not reviewed·Conditions: Fertility Disorders · Turner Syndrome · Premature Ovarian Failure·Matched via name phrase
Observational and natural-history studies
58 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06740656·NOT YET RECRUITING·Neuromuscular Complications of MEK Inhibitors: a French Case Series and a Systematic Review of the Literature
Not reviewed·Conditions: Myositis · Myasthaenia Gravis · Neuropathy · Guillain Barré Syndrome·Matched via name phrase
- NCT04463316·RECRUITING·GROWing Up With Rare GENEtic Syndromes
Not reviewed·Conditions: Prader-Willi Syndrome · PWS-like Syndrome · Silver Russel Syndrome · Congenital Hypopituitarism·Matched via name phrase
- NCT06507007·RECRUITING·Genetic and Epigenetic Background of Inner Ear Dysfunction in Turner Syndrome
Not reviewed·Conditions: Sensorineural Hearing Loss · Turner Syndrome · Inner Ear Disease·Matched via name phrase
- NCT06794190·RECRUITING·Characterization of Hepatopathy in Turner Syndrome: Analysis of Determinants
Not reviewed·Conditions: Turner Syndrome·Matched via name phrase
- NCT06178887·RECRUITING·Role of Cardiac AngioMR in Diagnosis of Cardiac and Vascular Anomalies in Adult Patients with Turner Syndrome
Not reviewed·Conditions: Anomaly Heart · Turner Syndrome·Matched via name phrase
- NCT06325618·RECRUITING·Lymphedema, Low-grade Inflammation and the Vasculature in Turner Syndrome
Not reviewed·Conditions: Turner Syndrome · Cardiovascular Diseases · Lymphedema · Inflammation·Matched via name phrase
- NCT02417740·RECRUITING·Natural History of Noncirrhotic Portal Hypertension
Not reviewed·Conditions: Cystic Fibrosis · Immunologic Deficiency Syndrome · Turner Syndrome · Congenital Hepatic Fibrosis·Matched via name phrase
- NCT07344012·RECRUITING·Parental Project Amongst 93 Patients With Turner Syndrome
Not reviewed·Conditions: Turner Syndrome·Matched via name phrase
- NCT01604395·RECRUITING·Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
Not reviewed·Conditions: Growth Hormone Deficiency · Turner Syndrome · Chronic Renal Failure · Small for Gestational Age·Matched via name phrase
- NCT04798690·RECRUITING·Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
Not reviewed·Conditions: Growth Hormone Deficiency · Idiopathic Short Stature · Turner Syndrome · Small for Gestational Age·Matched via name phrase
- NCT04948658·RECRUITING·Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
Not reviewed·Conditions: Turner Syndrome · Post-menarcheal Adolescents · Ovarian Disfunction · Galactosemia·Matched via name phrase
- NCT05052606·RECRUITING·Inspiring New Science In Guiding Healthcare in Turner Syndrome Registry
Not reviewed·Conditions: Turner Syndrome·Matched via name phrase
- NCT03812913·RECRUITING·Neuropsychological Assessment of Children and Adolescents With Turner Syndrome
Not reviewed·Conditions: Turner Syndrome · Isolated Growth Hormone Deficiency · Cognitive Functions · Social Cognition·Matched via name phrase
- NCT07502586·RECRUITING·Turner Syndrome: Genetic Considerations
Not reviewed·Conditions: Genetic·Matched via name phrase
- NCT03185702·RECRUITING·UTHealth Turner Syndrome Research Registry
Not reviewed·Conditions: Turner Syndrome·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 106 · after dedupe 103 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 103 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (103)
- isrctn·ISRCTN12491684·Recruiting·PATHWAYS TRIAL, PATHWAYS HORIZON INTENSIVE, PATHWAYS CONNECT
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN37340032·Recruiting·A study of bleximenib, venetoclax and azacitidine for treatment of participants with newly diagnosed acute myeloid leukemia (cAMeLot-2)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12803806·No longer recruiting·Machine learning to predict outcomes of type B aortic dissection patients following thoracic endovascular aortic repair
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN44436843·Recruiting·LACunar Intervention Trial 3
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN77727306·No longer recruiting·Impact of poor nutrition on survival rates in patients with aortic dissection undergoing heart surgery
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN72589181·Recruiting·A study to evaluate preventive treatments for talquetamab-related oral toxicity
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12054536·Recruiting·MiTiGate trial: Is Botox more effective than lidocaine and treatment as usual in myalgia temporomandibular disorder (TMD)?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15384496·No longer recruiting·The ARTEMIS trial is for patients who have been diagnosed as having a cancer of the lower bowel, known as the rectum. This study will examine the benefit of adding an additional treatment alongside radiotherapy and chemotherapy with the hope of increasing the chance of curing rectal cancer without the need for surgery.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17639209·No longer recruiting·A feasibility trial of the digital Hope Programme for adults with polycystic ovary syndrome (Hope PCOS)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57402067·Recruiting·A study comparing cancer patients randomly assigned to be offered either genetic testing ‘at home’ or in hospital
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73037722·Recruiting·LION: lifting immune checkpoints with NSAIDs
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN86607306·No longer recruiting·Pembrolizumab plus chemotherapy for diffuse large B-cell lymphoma that has come back or does not respond to treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83842641·Recruiting·A trial assessing preoperative chemotherapy in patients with locally advanced but operable colon cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN91141124·Recruiting·What is the most effective hormone treatment for women with premature ovarian insufficiency (POI), in both the short and long-term?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15563554·No longer recruiting·Repurposed drugs to improve blood counts and reduce transfusions in myelodysplastic syndromes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16993428·Recruiting·GenOMICC study - Looking at DNA of patients with severe illness and injury to find the genes that cause some people to become very unwell and be admitted to intensive care
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74656856·No longer recruiting·A study to evaluate the efficacy and safety of Lipoxim Fire for weight management in overweight healthy women
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16912075·No longer recruiting·RECOVERY Respiratory Support: Respiratory Strategies in patients with coronavirus COVID-19 – CPAP, high-flow nasal oxygen, and standard care
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12885480·Recruiting·Ruxolitinib versus hydroxycarbamide or interferon as first-line therapy in high-risk polcythemia vera
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11264442·Suspended·NEO21-RS: A prospective study of the outcomes following 21-gene recurrence score directed neoadjuvant therapy in ER-positive, HER2-negative breast cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN58892741·No longer recruiting·PARTNER: Platinum and PARP inhibitor for neoadjuvant treatment of triple-negative and/or BRCA-positive breast cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN48872100·No longer recruiting·Preventing gestational diabetes with myo-inositol supplement
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11965217·No longer recruiting·A trial to assess whether the addition of atezolizumab to current standard treatment for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma, who are not able to have high dose therapy, improves survival outcomes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN53348826·No longer recruiting·Renal Adjuvant Multiple Arm Randomised Trial (RAMPART)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14240288·No longer recruiting·Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer?
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Turner syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26Directly listed under NPRD Group 2.
Group 2 — long-term / lifelong lower-cost interventions
NPRD envisages State Government support for dietary formulae, hormones, and other lower-cost interventions. This is a different route from the central CoE ₹50 lakh pathway; ask your state health department and a CoE which channel applies.
Central CoE funding may also apply depending on current rules — confirm with a notified Centre of Excellence. Do not assume the ₹50 lakh ceiling covers Group 2 by default. Verify
Centres of Excellence (15)
- All India Institute of Medical Sciences (AIIMS) — New Delhi, Delhi
- Maulana Azad Medical College — New Delhi, Delhi
- Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
- Post Graduate Institute of Medical Education and Research (PGIMER) — Chandigarh, Chandigarh
- Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical Sciences — Hyderabad, Telangana
- King Edward Memorial Hospital — Mumbai, Maharashtra
- Institute of Post-Graduate Medical Education and Research (IPGMER) — Kolkata, West Bengal
- Centre for Human Genetics with Indira Gandhi Hospital — Bengaluru, Karnataka
- Institute of Child Health and Hospital for Children (ICH & HC) — Chennai, Tamil Nadu
- All India Institute of Medical Sciences (AIIMS) — Jodhpur, Rajasthan
- Sree Avittam Thirunal Hospital (SAT), Government Medical College — Thiruvananthapuram, Kerala
- All India Institute of Medical Sciences (AIIMS) — Bhopal, Madhya Pradesh
- Regional Institute of Medical Sciences (RIMS) — Imphal, Manipur
- All India Institute of Medical Sciences (AIIMS) — Patna, Bihar
- Assam Medical College & Hospital — Dibrugarh, Assam
Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Turner syndrome" OR "45,X syndrome" OR "45,X/46,XX syndrome" OR "45,X gonadal dysgenesis" OR "45,X0 syndrome" OR "45X syndrome" OR "karyotype 45, X"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Turner syndrome" OR "45,X syndrome" OR "45,X/46,XX syndrome" OR "45,X gonadal dysgenesis" OR "45,X0 syndrome" OR "45X syndrome" OR "karyotype 45, X"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 47 interventional · 58 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T15:44:20.006Z
